Arcutis Biotherapeutics News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Arcutis biotherapeutics. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Arcutis Biotherapeutics Today - Breaking & Trending Today

Avidity Up 33% on Rare Muscle Disease Study Results - Arcutis Biotherapeutics (NASDAQ:ARQT), Heron Therapeutics (NASDAQ:HRTX)

Avidity Biosciences (NASDAQ: RNA) announced encouraging initial data from the phase I/II FORTITUDE study evaluating two doses of delpacibart braxlosiran (del-brax, or formerly AOC 1020) in facioscapulohumeral muscular dystrophy (FSHD), a rare genetic disease of the muscles. ....

United States , Marinus Pharmaceuticals , Arcutis Biotherapeutic , Heron Therapeutics , Arcutis Biotherapeutics , Earnings Of Marinus Pharmaceuticals , Society International Research Congress , Avidity Biosciences Inc , Avidity Bioscience , International Research Congress , Avidity Biosciences , Zacks Rank , Marinus Pharmaceutical , Heron Therapeutic ,

Frazier Life Sciences Management L.P. Has $28.31 Million Holdings in Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT)

Frazier Life Sciences Management L.P. grew its holdings in Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT – Free Report) by 0.9% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 8,764,232 shares of the company’s stock after buying an additional 80,000 shares during […] ....

Larry Todd Edwards , Cantor Fitzgerald , Arcutis Biotherapeutics , Patrick Burnett , Capital Management , Ghisallo Capital Management , Needham Company , Arcutis Biotherapeutics Inc , Securities Exchange Commission , Goldman Sachs Group , Venture Partners Investment Advisor , Frazier Life Sciences Management , Free Report , Get Free Report , Exchange Commission , Todd Edwards , Visit Holdingschannel ,

Frazier Life Sciences Management L.P. Has $28.31 Million Holdings in Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT)

Frazier Life Sciences Management L.P. grew its holdings in Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT – Free Report) by 0.9% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 8,764,232 shares of the company’s stock after buying an additional 80,000 shares during […] ....

Larry Todd Edwards , Patrick Burnett , Arcutis Biotherapeutics , Cantor Fitzgerald , Goldman Sachs Group , Securities Exchange Commission , Arcutis Biotherapeutics Inc , Venture Partners Investment Advisor , Frazier Life Sciences Management , Ghisallo Capital Management , Capital Management , Needham Company , Free Report , Get Free Report , Exchange Commission , Todd Edwards , Visit Holdingschannel ,

Patrick Burnett Sells 23,000 Shares of Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Stock

Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT – Get Free Report) insider Patrick Burnett sold 23,000 shares of Arcutis Biotherapeutics stock in a transaction on Thursday, May 30th. The shares were sold at an average price of $8.75, for a total transaction of $201,250.00. Following the completion of the sale, the insider now owns 209,793 shares of the […] ....

Patrick Burnett , Arcutis Biotherapeutics , Swiss National Bank , Goldman Sachs Group , Arcutis Biotherapeutics Inc , Arcutis Biotherapeutics Company Profile , Wadegw Inc , Jump Financial , Needham Company , York Mellon Corp , Get Free Report , New York Mellon Corp , National Bank ,

Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Insider Patrick Burnett Sells 23,000 Shares

Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT – Get Free Report) insider Patrick Burnett sold 23,000 shares of the stock in a transaction that occurred on Thursday, May 30th. The stock was sold at an average price of $8.75, for a total value of $201,250.00. Following the sale, the insider now directly owns 209,793 shares of the company’s […] ....

Los Angeles , United States , Dekabank Deutsche Girozentrale , Patrick Burnett , Arcutis Biotherapeutics , Goldman Sachs Group , Arcutis Biotherapeutics Inc , Needham Company , China Universal Asset Management Co , Los Angeles Capital Management , Get Free Report , Bank Deutsche Girozentrale , Angeles Capital Management , Universal Asset Management , Trexquant Investment ,